Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Osimertinib

* Plasma ctDNA before surgery (optional)
* Plasma ctDNA post-surgery : 4 to 8 weeks post-surgery, before starting adjuvant chemotherapy (if given) and before starting adjuvant osimertinib (if given)
* Plasma ctDNA every 6 months
* Plasma ctDNA at relapse

Plasma ctDNA

* Surgery FFPE blocks
* FFPE blocks at relapse (optional)

FFPE blocks

Youssef OULKHOUIR

Youssef OULKHOUIR, Dr

Sophie SCHNEIDER

Sophie SCHNEIDER, Dr

Etienne GIROUX LEPRIEUR

Etienne GIROUX LEPRIEUR, Pr

Thomas PIERRET

Thomas PIERRET, Dr

Jeannick MADELAINE

Jeannick MADELAINE, Dr

Patrick MERLE

Lionel MOREAU

Lionel MOREAU, Dr

Isabelle MONNET

Isabelle MONNET, Dr

Ayoube ZOUAK

Ayoube ZOUAK, Dr

Anne-Claire TOFFART

Anne-Claire TOFFART, Pr

Cyril GUIBERT

Cyril GUIBERT, Dr

Dr Camille GUGUEN

Dr Camille GUGUEN, Dr

Alexis CORTOT

Alexis CORTOT, Pr

Virginie AVRILLON

Virginie AVRILLON, Dr

Pascale TOMASINI

Pascale TOMASINI, Dr

Benoît GODBERT, Dr

Benoît GODBERT

Benoit ROCH

Benoit ROCH, Dr

Quentin THOMAS

Quentin THOMAS, Dr

Jonathan BENZAQUEN

Jonathan BENZAQUEN, Dr

Hugues MOREL

Hugues MOREL, Dr

Gérard ZALCMAN

Gérard ZALCMAN, Pr

Elizabeth FABRE

Elizabeth FABRE, Dr

Marie WISLEZ

Marie WISLEZ, Pr

Aurore VOZY

Aurore VOZY, Dr

Pr Jacques CADRANEL

Pr Jacques CADRANEL, Pr

Aldo RENAULT

Aldo RENAULT, Dr

Maéva ZYSMAN

Maéva ZYSMAN, Dr

Clotilde DELDYCKE

Clotilde DELDYCKE, Dr

Valérie PAULUS-JACQUEMET

Valérie PAULUS-JACQUEMET, Dr

Charles RICORDEL

Charles RICORDEL, Dr

Florian GUISIER

Florian GUISIER, Pr

Céline MASCAUX, Dr

Céline MASCAUX, Pr

Alexandra BIZOT

Alexandra BIZOT, Dr

Clarisse AUDIGIER-VALETTE

Clarisse AUDIGIER-VALETTE, Dr

Laurence BIGAY-GAME

Laurence BIGAY-GAME, Dr

Delphine Carmier

Delphine Carmier, Dr

IFCT-2202 ROSIE study aims to incorporate a broad-panel centralized NGS testing at baseline in all patients with completely resected NSCLC with common EGFR mutation after confirmation of an optimal preoperative extension assessment and with a centralized review of the quality of the surgical excision. Furthermore, the IFCT-2202 ROSIE study also aims to study the molecular events associated with relapse on, or after osimertinib exposure, that should result in the opportunity to accede to optimal treatment in case of metastatic relapse.

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Number of patients included receiving osimertinib after 18 months of enrollment

Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0).

Intergroupe Francophone de Cancerologie Thoracique

Spots Global Cancer Trial Database for egfr del19

Every month we try and update this database with for egfr del19 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for egfr del19

Every month we try and update this database with for egfr del19 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for egfr del19 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.